InflaRx (IFRX) Other Non-Current Assets (2016 - 2026)
InflaRx (IFRX) posted Other Non-Current Assets of $162958.4 for Q1 2026, down 7.41% sequentially from $176001.1 in Q4 2025, and down 18.88% YoY from $200882.6 in Q1 2025.
InflaRx (IFRX) Other Non-Current Assets (2016 - 2026) Analysis & Trends
InflaRx has reported Other Non-Current Assets for 11 years, with the latest figure at $162958.4 in Q1 2026.
- Quarterly Other Non-Current Assets fell 18.88% year-over-year to $162958.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $162958.4 (down 18.88% YoY) and the FY2025 annual result came in at $170825.2, down 99.14% from the prior year.
- Other Non-Current Assets slipped to $162958.4 in Q1 2026 per IFRX's latest filing, from $176001.1 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $19.7 million in Q4 2024 and troughed at $162958.4 in Q1 2026.
- A 5-year average of $1.6 million and a median of $294492.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets jumped 7003.28% in 2024, then tumbled 99.1% in 2025.
- Over 5 years, Other Non-Current Assets stood at $314303.5 in 2022, then declined by 11.93% to $276803.8 in 2023, then surged by 7003.28% to $19.7 million in 2024, then sank by 99.1% to $176001.1 in 2025, then retreated by 7.41% to $162958.4 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $162958.4, $176001.1, and $192259.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 146,691.23 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162,958.43 |
| Dec 31, 2025 | 176,001.05 |
| Sep 30, 2025 | 192,259.29 |
| Jun 30, 2025 | 201,167.35 |
| Mar 31, 2025 | 200,882.58 |
| Dec 31, 2024 | 19.66 Mn |
| Sep 30, 2024 | 4.08 Mn |
| Jun 30, 2024 | 248,491.81 |
| Mar 31, 2024 | 265,082.05 |
| Dec 31, 2023 | 276,803.83 |
| Sep 30, 2023 | 294,492.03 |
| Jun 30, 2023 | 309,019.32 |
| Mar 31, 2023 | 318,805.06 |
| Dec 31, 2022 | 314,303.52 |
| Sep 30, 2022 | 353,470.73 |
| Jun 30, 2022 | 364,576.99 |
| Mar 31, 2022 | 372,098.72 |
| Dec 31, 2021 | 385,021.73 |
| Sep 30, 2021 | 401,632.24 |
| Jun 30, 2021 | 412,943.47 |